Maraviroc
Maraviroc is an antiretroviral medication used to treat HIV-1 infection in combination with other antiviral drugs. It belongs to a class called CCR5 antagonists and is specifically effective against CCR5-tropic HIV-1 strains. This medication is typically prescribed for treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple other antiretroviral agents.
Maraviroc is an HIV-1 entry inhibitor that blocks the CCR5 co-receptor to prevent the virus from entering healthy cells, used in combination therapy for treatment-experienced patients.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- J05AX09
- RxNorm
- 620216
- Generic
- Maraviroc
- Class
- atc-j05
- Brands
- Selzentry
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet, solution
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Maraviroc is indicated for combination antiretroviral treatment of adults with CCR5-tropic HIV-1 infection who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. It is not effective against CXCR4-tropic or dual/mixed-tropic HIV-1 strains.
Maraviroc is a CCR5 antagonist that works by selectively binding to the human CCR5 co-receptor on the surface of CD4 T-cells. This blocks the interaction between the HIV-1 envelope glycoprotein gp120 and the CCR5 co-receptor, preventing viral entry into uninfected cells.
Tropism testing must be performed before initiating treatment to confirm CCR5-tropic HIV-1. Maraviroc is taken orally twice daily with or without food. Common side effects may include cough, fever, rash, and abdominal pain. It interacts with other medications metabolized by CYP3A enzymes. Liver toxicity and severe skin reactions have been reported. Patients should be monitored for signs of infection or immune reconstitution syndrome.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy